Predicting outcomes for MASLD-related cirrhosis
Part of Digestive system, Hormones & metabolism clinical trials.
This study is building a model to better predict how metabolic liver disease (MASLD) that has led to cirrhosis (scarring of the liver) will progress. If you have compensated cirrhosis (your liver is still working well) and have been diagnosed with MASLD or a related condition, this research could help develop more personalized care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with cirrhosis caused by fat buildup in the liver (MASLD). This diagnosis can be based on a liver biopsy or non-invasive tests like FibroScan or MRI.
- Your cirrhosis is compensated, meaning your liver is still functioning well and you have not had serious complications like fluid in the belly, bleeding from veins, or mental confusion.
- You have two or more metabolic risk factors, such as being overweight, having prediabetes, or type 2 diabetes.
- You do not have other causes of liver disease like hepatitis C, heavy alcohol use, or autoimmune hepatitis.
- You have not had heavy drinking (more than 1 drink per day for women or 2 drinks per day for men) in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This trial uses digital twin technology to better detect, treat, and monitor metabolic fatty liver disease (MAFLD) and its complications like heart disease and cirrhosis. It may help create more personalized care plans.
This study looks at factors that predict liver cancer and the need for a liver transplant in people with a liver condition called MASLD (metabolic dysfunction-associated steatotic liver disease). The goal is to better understand the disease and improve care.
This study tests a new screening tool to find advanced liver scarring in people with liver disease linked to diabetes. It helps doctors decide who needs more tests or specialist care.
This study is testing whether an MRI can help doctors see liver scarring (fibrosis) in people with MASLD, a type of fatty liver disease. It is for patients who already need a liver biopsy as part of their care, to compare the MRI results with the biopsy.
Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.